Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review

9Citations
Citations of this article
152Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages.

Cite

CITATION STYLE

APA

Dai, J., Xiong, Y., Li, H., Qian, Y., Xu, Y., Xu, Q., … Tang, J. (2020, July 1). Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clinical Rheumatology. Springer. https://doi.org/10.1007/s10067-020-05172-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free